These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 5535910)

  • 1. Thyroid gland in Graves' disease: victim or culprit?
    Chopra IJ; Solomon DH; Johnson DE; Chopra U
    Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppressibility of thyroid function despite high levels of long-acting thyroid stimulator.
    Wong ET; Doe RP
    Ann Intern Med; 1972 Jan; 76(1):77-84. PubMed ID: 4112158
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypothyroidism with unusual features following propylthiouracil therapy of Graves' disease.
    Pittman JG; Maloof F
    Am J Med Sci; 1972 Dec; 264(6):499-505. PubMed ID: 4119609
    [No Abstract]   [Full Text] [Related]  

  • 4. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 5. Inappropriate suppression of thyrotropin during medical treatment of Graves disease in childhood.
    Sills IN; Horlick MN; Rapaport R
    J Pediatr; 1992 Aug; 121(2):206-9. PubMed ID: 1640284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
    Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
    J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
    [No Abstract]   [Full Text] [Related]  

  • 7. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
    Chopra IJ; Chopra U; Orgiazzi J
    J Clin Endocrinol Metab; 1973 Dec; 37(6):955-67. PubMed ID: 4201831
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease.
    Földes J; Gyertyánfy G; Tako J; Bános C; Gesztesi E
    Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
    Silverstein GE; Burke G
    Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
    [No Abstract]   [Full Text] [Related]  

  • 10. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
    Buerklin EM; Schimmel M; Utiger RD
    J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressibility of thyroid function during treatment with antithyroid drugs in Grave's disease.
    Wils JA; Kloppenborg PW
    J Clin Endocrinol Metab; 1970 Mar; 30(3):406-7. PubMed ID: 4189571
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 13. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
    McKenzie JM; Zakarija M; D'Amour P; Joasoo A
    N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
    [No Abstract]   [Full Text] [Related]  

  • 14. Thyroidal effects of injections of Graves' disease thyroid microsomes in rhesus monkeys.
    Furth ED; Dentinger M
    Endocrinology; 1971 Jul; 89(1):310-5. PubMed ID: 4103749
    [No Abstract]   [Full Text] [Related]  

  • 15. Thyrotrophin response to thyrotrophin-releasing hormone in ophthalmic Graves' disease: correlation with other aspects of thyroid function, thyroid suppressibility and activity of eye signs.
    Ormston BJ; Alexander L; Evered DC; Clark F; Bird T; Appleton D; Hall R
    Clin Endocrinol (Oxf); 1973 Oct; 2(4):369-76. PubMed ID: 4128973
    [No Abstract]   [Full Text] [Related]  

  • 16. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine.
    Yamamoto M; Igarashi T; Kimura S; Tsukamoto S; Togawa K; Ogata E
    J Clin Endocrinol Metab; 1979 Jan; 48(1):72-7. PubMed ID: 581766
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts in management of thyroid disease.
    DeGroot LJ
    Med Clin North Am; 1970 Jan; 54(1):117-30. PubMed ID: 4189143
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.